Navigation Links
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Date:10/11/2011

his group progressed multiple novel drugs targeting protein homeostasis into development. At Millennium he also spent two years as the VELCADE® Discovery Leader, during which time the drug received a number of regulatory approvals. Prior experience includes research positions at Mitotix Inc. and Celltech Ltd.

Based in Cleave Biosciences' Burlingame, California laboratories, Scientific Co-Founder Dr. Parlati serves as Senior Director of Biology. Prior to working with Drs. Deshaies and Cohen on the Cleave technology, he was Associate Director at Proteolix where he was instrumental in the development of oncology drug candidate carfilzomib and PR-957 (now ONX 0914), currently in preclinical studies.

Scientific Co-Founders Drs. Deshaies and Cohen are acting as advisors to the company. A world-renowned expert in the study of protein degradation pathways and previously a Co-Founder of Proteolix, Dr. Deshaies is Professor and Executive Officer of Biology at the California Institute of Technology and an Investigator of the Howard Hughes Medical Institute. Dr. Cohen is Professor of Chemistry and Biochemistry at the University of California, San Diego and known internationally for his work in metalloprotease inhibition.

In conjunction with this financing, Cleave Biosciences named several individuals to its board of directors: Dennis Henner, Ph.D., Managing Partner at Clarus Ventures; Larry Lasky, Ph.D., Partner at U.S. Venture Partners; Andrew J. Schwab, Managing Partner at 5AM Ventures;  Peter Thompson, M.D., Cleave Biosciences Founder and Venture Partner at OrbiMed Advisors; and Dr. Shawver.


'/>"/>
SOURCE Cleave Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amarillo Biosciences Teams with Animal Shelters to Improve Health and Enhance Immunity of Cats and Dogs
2. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
3. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
4. Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
5. Avantra Biosciences Changes Company Name to Courtagen Life Sciences, Inc.
6. BD Biosciences Announces Winners of Research Grant Program
7. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
8. Numira Biosciences Names New Board Member
9. Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
10. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
11. BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and PARIS , July ... Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that ... Drug Administration (FDA) rare pediatric disease priority review voucher ... for alirocumab.  The priority review voucher entitles the holder ... for an expedited 6-month review from the filing date ...
(Date:7/30/2014)... FRANCISCO , July 30, 2014 ... Congress evaluated the safety and efficacy of CSL ... rejection following kidney transplants in highly sensitized patients. ... inhibitor of the complement system. The ... in significant increases in the levels of complement ...
(Date:7/30/2014)... 30, 2014 While administrative claims ... services research for a relatively long period of ... regarding the use of these ‘big data’ for ... By combining today’s powerful computer technology with the ... ‘big data’ holds significant promise for identifying optimal ...
(Date:7/30/2014)... July 30, 2014   Wyle has ... Integrated Lifecycle Mission Support Services (FILMSS) contract awarded ... Under the terms of the contract, Wyle will ... Moffett Field, Calif. In particular, Wyle will provide ... development projects on the International Space Station and ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2
... ("Bioponic" or "the Company") (OTC: BPYT) today announced that ... to sales for the month,of January 2007., "We ... primarily,from continued success of our Flight Spray product. We ... an all-natural solution for,baby care marketed under the Gentle ...
... /Xinhua-PRNewswire/ -- China Shenghuo,Pharmaceutical Holdings, Inc. ("China ... in the research, development, manufacture, and,marketing of ... People,s Republic of China ("PRC"), today announced ... products in the United States during the,first ...
... Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned subsidiary of ... received tentative approval from the U.S. Food,and Drug ... and 40 mg (base). Nexium(R) (Esomeprazole) is the,second ... annual market sales of,$5.5 billion (IMS -- MAT: ...
Cached Biology Technology:Bioponic Phytoceuticals Announces Record Sales Increase of 40% for the Month of January 2China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group 2China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group 3Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules 2
(Date:7/30/2014)... Helsinki and the Universitat Autnoma de Barcelona have been ... have taken millions of years to occur. Through small ... teeth, induced in the laboratory, scientists have obtained teeth ... the fossil registry of rodent species which separated from ... the development of their teeth, the team from the ...
(Date:7/30/2014)... to announce its new relationship with the International College ... will partner to publish International Journal of Neuropsychopharmacology ... , Alan Frazer, Editor-in-Chief of IJNP said, ... OUP will further facilitate the goal for the ... journals within neuropsychopharmacology. The conversion of the IJNP ...
(Date:7/30/2014)... has received a pledge of $1 million from the ... Laboratory,s new Neurobehavioral Biometry Center. , The ... enable the Laboratory to develop a greater breadth and ... goal of accelerating the pace of research to improve ... a premier resource for the Laboratory and its external ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2OUP to partner with the International College of Neuropsychopharmacology 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... visual centers of men and women,s brains works is ... access journal Biology of Sex Differences . Men ... stimuli, but women are better at discriminating between colors. ... male sex hormone (androgen) receptors throughout cerebral cortex, especially ...
... for up to twelve weeks could dramatically improve the ... developed the new technology are presenting their work at ... University of Warwick. Researchers at the University of ... urinary bacteria, including most strains of Proteus bacteria ...
... proportion of HIV-infected patients in the U.S. receiving effective ... and HIV-infected patients appeared to be less infectious and ... study led by researchers at the Johns Hopkins Bloomberg ... the NA-ACCORD (North American AIDS Cohort Collaboration on Research ...
Cached Biology News:The eyes have it: Men do see things differently to women 2New long-term antimicrobial catheter developed 2HIV treatment use increases in the US 2
...
... high-throuput screening of a biological systems phenotype, ... changes in the expression levels of the ... studied, classified and compared to each other, ... a glance. Automatized scanning of the hybridized ...
Rabbit polyclonal to Esa1 ( Abpromise for all tested applications)....
RORgamma (S-14)...
Biology Products: